{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(3)"],"submitter":["Tran MC"],"pubmed_abstract":["Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse rate remains high. We conducted a single-center, phase 1, modified 3 + 3 dose-escalation study of the feasibility of combining intensity-modulated total marrow irradiation (IM-TMI) with fludarabine and melphalan for conditioning. Between December 2015 and May 2020, 21 patients with relapsed hematologic disease undergoing second or greater allo-SCT were treated with IM-TMI doses of 6 Gy, 9 Gy, or 12 Gy. Dose-limiting toxicity was defined as a grade 3 or higher treatment-related adverse event; mucositis was the primary dose-limiting toxicity. The median times to neutrophil and platelet engraftment "],"journal":["Blood advances"],"pagination":["285-292"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9898602"],"repository":["biostudies-literature"],"pubmed_title":["A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT."],"pmcid":["PMC9898602"],"pubmed_authors":["Liu H","Artz AS","Wang A","Hasan Y","Stock W","Larson RA","Kline J","Weichselbaum R","Aydogan B","Tran MC","Riedell PA","Bishop MR","Yenice K","Partouche J","Kosuri S","LaBelle JL"],"additional_accession":[]},"is_claimable":false,"name":"A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.","description":"Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse rate remains high. We conducted a single-center, phase 1, modified 3 + 3 dose-escalation study of the feasibility of combining intensity-modulated total marrow irradiation (IM-TMI) with fludarabine and melphalan for conditioning. Between December 2015 and May 2020, 21 patients with relapsed hematologic disease undergoing second or greater allo-SCT were treated with IM-TMI doses of 6 Gy, 9 Gy, or 12 Gy. Dose-limiting toxicity was defined as a grade 3 or higher treatment-related adverse event; mucositis was the primary dose-limiting toxicity. The median times to neutrophil and platelet engraftment ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-27T02:57:10.52Z","creation":"2025-04-06T18:38:59.111Z"},"accession":"S-EPMC9898602","cross_references":{"pubmed":["35851593"],"doi":["10.1182/bloodadvances.2022007530"]}}